CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nutra Pharma Corp. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nutra Pharma Corp.
1537 NW 65th Avenue
Phone: (954) 509-0911p:954 509-0911 PLANTATION, FL  33313  United States Ticker: NPHCNPHC
Business Summary
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company's drug candidates include RPI-MN and RPI-78M. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin and Pet Pain-Away. Its pain relief categories include arthritis pain, chronic back pain, headaches and migraines, and knee and joint pain. Its over the counter (OTC) homeopathic products include Nyloxin Topical Gel, Extra Strength Nyloxin Topical Gel, Nyloxin Oral Spray, Extra Strength Nyloxin Oral Spray, Nyloxin Topical Gel Roll On, Nyloxin Professional Size Pump Topical Gel and Pet Pain Away. The Company's holds approximately 21 patents in their portfolio.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202212/31/2021YesYesYesYesYes

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Chief Financial Officer Michael D.Flax 69 3/20/2024 11/26/2001
Chief Scientific Officer DaleVanderputten 60 7/27/2016 7/27/2016
Director StewartLonky 73 11/5/2004 11/5/2004
Director Garry R.Pottruck 63 7/29/2009 7/29/2009

Business Names
Business Name
Designer Diagnostics, Inc.
NPHC
NUTRA PHARMA CORP
ReceptoPharm, Inc.

General Information
Number of Employees: 4 (As of 12/31/2021)
Outstanding Shares: 7,596,852,214 (As of 11/21/2022)
Shareholders: 288
Stock Exchange: OTC
Federal Tax Id: 912021600
Fax Number: (877) 895-5647


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, February 1, 2025